¿ Connetics Corp., of Palo Alto, Calif., received a milestone payment of $878,000 from Suntory Pharmaceuticals, of Osaka, Japan, because Connetics began a pivotal trial of ConXn (human recombinant relaxin) for the treatment of sclerodoma.
¿ Immunex Corp., of Seattle, launched a Phase II trial of its CD40 Ligand in renal cell carcinoma, based on results of a multi-dose Phase I trial in advanced cancer patients.
¿ NeoTherapeutics Inc., of Irvine, Calif., completed a private placement of 400,000 shares of common stock and warrants to purchase 80,000 shares of common stock to a group of private investors for $4 million. All investors are clients of Ingalls & Snyder LLC, of New York.
¿ Ribozyme Pharmaceuticals Inc., of Boulder, Colo., received $7.5 million for purchase of stock in accordance with its agreement with Eli Lilly and Co., of Indianapolis, to collaborate on the research, development and commercialization of ribozymes for the treatment of hepatitis C. (See BioWorld Today, March 24, 1999, p. 1.)
¿ Xoma Ltd., of Berkeley, Calif., concluded patient accrual in its Phase III pivotal trial of Neuprex for severe pediatric meningococcemia, a deadly bacterial infection. The decision to close enrollment was made after consultation with the FDA. Nearly 400 patients have been enrolled.